Blueprint Medicines Corp BPMC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Blueprint Medicines to Present at Upcoming Investor Conferences
-
Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
-
Investors Have the Opportunity to Join the Following Securities Fraud Investigations: Avangrid, Inc. (AGR), Squarespace, Inc. (SQSP), and Blueprint Medicines Corporation (BPMC)
-
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024
-
Investors Have the Opportunity to Join the Following Securities Fraud Investigations: Avangrid, Inc. (AGR), Squarespace, Inc. (SQSP), and Blueprint Medicines Corporation (BPMC)
-
Cogent Biosciences stock drops as analysts see tough competition for mastocytosis treatment
Trading Information
- Previous Close Price
- $89.06
- Day Range
- $89.94–94.70
- 52-Week Range
- $43.89–121.90
- Bid/Ask
- $80.00 / $97.00
- Market Cap
- $5.86 Bil
- Volume/Avg
- 16 / 686,734
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 16.00
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 655
Comparables
Valuation
|
Metric
|
BPMC
|
EXEL
|
ATXS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 17.02 | — |
Price/Book Value | 18.25 | 3.49 | 2.43 |
Price/Sales | 16.00 | 3.97 | — |
Price/Cash Flow | — | 16.25 | — |
Price/Earnings
BPMC
EXEL
ATXS
Financial Strength
|
Metric
|
BPMC
|
EXEL
|
ATXS
|
|---|---|---|---|
Quick Ratio | 3.48 | 4.05 | 21.67 |
Current Ratio | 3.71 | 4.27 | 21.87 |
Interest Coverage | −8.43 | — | — |
Quick Ratio
BPMC
EXEL
ATXS
Profitability
|
Metric
|
BPMC
|
EXEL
|
ATXS
|
|---|---|---|---|
Return on Assets (Normalized) | −24.11% | 14.82% | −24.27% |
Return on Equity (Normalized) | −104.04% | 19.05% | −39.29% |
Return on Invested Capital (Normalized) | −41.57% | 14.99% | −30.47% |
Return on Assets
BPMC
EXEL
ATXS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Vxmgvlgcv | Ssky | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Qnymtqnly | Drlszfj | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Qdvcdpjzk | Spgnbzt | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Pwfhgvjxp | Lxccph | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Zpkgxrhnw | Qsp | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Cvzmgpdr | Pzgfc | $28.1 Bil | |||
| Moderna Inc
MRNA
| Vdlbvhhwb | Jqk | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Xlyhjqcw | Sfpch | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Scpmfycm | Rbfrytb | $13.4 Bil | |||
| Incyte Corp
INCY
| Yqbzryffq | Mjlvzp | $12.7 Bil |
United States